Cargando…
Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study
OBJECTIVES: To evaluate the performance of individual biomarkers and a multi-biomarker disease activity (MBDA) score in the early rheumatoid arthritis (RA) patient population from the computer assisted management in early rheumatoid arthritis (CAMERA) study. METHODS: Twenty biomarkers were measured...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Group
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439649/ https://www.ncbi.nlm.nih.gov/pubmed/22596166 http://dx.doi.org/10.1136/annrheumdis-2011-200963 |
_version_ | 1782243040366166016 |
---|---|
author | Bakker, Marije F Cavet, Guy Jacobs, Johannes WG Bijlsma, Johannes W J Haney, Douglas J Shen, Yijing Hesterberg, Lyndal K Smith, Dustin R Centola, Michael van Roon, Joel A G Lafeber, Floris P J G Welsing, Paco M J |
author_facet | Bakker, Marije F Cavet, Guy Jacobs, Johannes WG Bijlsma, Johannes W J Haney, Douglas J Shen, Yijing Hesterberg, Lyndal K Smith, Dustin R Centola, Michael van Roon, Joel A G Lafeber, Floris P J G Welsing, Paco M J |
author_sort | Bakker, Marije F |
collection | PubMed |
description | OBJECTIVES: To evaluate the performance of individual biomarkers and a multi-biomarker disease activity (MBDA) score in the early rheumatoid arthritis (RA) patient population from the computer assisted management in early rheumatoid arthritis (CAMERA) study. METHODS: Twenty biomarkers were measured in the CAMERA cohort, in which patients were treated with either intensive or conventional methotrexate-based treatment strategies. The MBDA score was calculated using the concentrations of 12 biomarkers (SAA, IL-6, TNF-RI, VEGF-A, MMP-1, YKL-40, MMP-3, EGF, VCAM-1, leptin, resistin and CRP) according to a previously trained algorithm. The performance of the scores was evaluated relative to clinical disease activity assessments. Change in MBDA score over time was assessed by paired Wilcoxon rank sum test. Logistic regression was used to evaluate the ability of disease activity measures to predict radiographic progression. RESULTS: The MBDA score had a significant correlation with the disease activity score based on 28 joints-C reactive protein (DAS28-CRP) (r=0.72; p<0.001) and an area under the receiver operating characteristic curve for distinguishing remission/low from moderate/high disease activity of 0.86 (p<0.001) using a DAS28-CRP cut-off of 2.7. In multivariate analysis the MBDA score, but not CRP, was an independent predictor of disease activity measures. Additionally, mean (SD) MBDA score decreased from 53 (18) at baseline to 39 (16) at 6 months in response to study therapy (p<0.0001). Neither MBDA score nor clinical variables were predictive of radiographic progression. CONCLUSIONS: This multi-biomarker test performed well in the assessment of disease activity in RA patients in the CAMERA study. Upon further validation, this test could be used to complement currently available disease activity measures and improve patient care and outcomes. |
format | Online Article Text |
id | pubmed-3439649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BMJ Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-34396492012-09-12 Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study Bakker, Marije F Cavet, Guy Jacobs, Johannes WG Bijlsma, Johannes W J Haney, Douglas J Shen, Yijing Hesterberg, Lyndal K Smith, Dustin R Centola, Michael van Roon, Joel A G Lafeber, Floris P J G Welsing, Paco M J Ann Rheum Dis Clinical and Epidemiological Research OBJECTIVES: To evaluate the performance of individual biomarkers and a multi-biomarker disease activity (MBDA) score in the early rheumatoid arthritis (RA) patient population from the computer assisted management in early rheumatoid arthritis (CAMERA) study. METHODS: Twenty biomarkers were measured in the CAMERA cohort, in which patients were treated with either intensive or conventional methotrexate-based treatment strategies. The MBDA score was calculated using the concentrations of 12 biomarkers (SAA, IL-6, TNF-RI, VEGF-A, MMP-1, YKL-40, MMP-3, EGF, VCAM-1, leptin, resistin and CRP) according to a previously trained algorithm. The performance of the scores was evaluated relative to clinical disease activity assessments. Change in MBDA score over time was assessed by paired Wilcoxon rank sum test. Logistic regression was used to evaluate the ability of disease activity measures to predict radiographic progression. RESULTS: The MBDA score had a significant correlation with the disease activity score based on 28 joints-C reactive protein (DAS28-CRP) (r=0.72; p<0.001) and an area under the receiver operating characteristic curve for distinguishing remission/low from moderate/high disease activity of 0.86 (p<0.001) using a DAS28-CRP cut-off of 2.7. In multivariate analysis the MBDA score, but not CRP, was an independent predictor of disease activity measures. Additionally, mean (SD) MBDA score decreased from 53 (18) at baseline to 39 (16) at 6 months in response to study therapy (p<0.0001). Neither MBDA score nor clinical variables were predictive of radiographic progression. CONCLUSIONS: This multi-biomarker test performed well in the assessment of disease activity in RA patients in the CAMERA study. Upon further validation, this test could be used to complement currently available disease activity measures and improve patient care and outcomes. BMJ Group 2012-10 /pmc/articles/PMC3439649/ /pubmed/22596166 http://dx.doi.org/10.1136/annrheumdis-2011-200963 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/3.0/ and http://creativecommons.org/licenses/by-nc/3.0/legalcode |
spellingShingle | Clinical and Epidemiological Research Bakker, Marije F Cavet, Guy Jacobs, Johannes WG Bijlsma, Johannes W J Haney, Douglas J Shen, Yijing Hesterberg, Lyndal K Smith, Dustin R Centola, Michael van Roon, Joel A G Lafeber, Floris P J G Welsing, Paco M J Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study |
title | Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study |
title_full | Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study |
title_fullStr | Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study |
title_full_unstemmed | Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study |
title_short | Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study |
title_sort | performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the camera tight control study |
topic | Clinical and Epidemiological Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439649/ https://www.ncbi.nlm.nih.gov/pubmed/22596166 http://dx.doi.org/10.1136/annrheumdis-2011-200963 |
work_keys_str_mv | AT bakkermarijef performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT cavetguy performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT jacobsjohanneswg performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT bijlsmajohanneswj performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT haneydouglasj performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT shenyijing performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT hesterberglyndalk performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT smithdustinr performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT centolamichael performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT vanroonjoelag performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT lafeberflorispjg performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy AT welsingpacomj performanceofamultibiomarkerscoremeasuringrheumatoidarthritisdiseaseactivityinthecameratightcontrolstudy |